Since the foundation of Dalmia Research and Development Limited in 2000, Dalmia, R & D Group has continued its evolution. DRDL has transformed the Contract Research Organization portfolio and focused on the core business of pharmaceutical clinical trials, Bio equivalence and Bio availability studies, Pre-clinical study, Clinical research on new drug formulations, Testing and trial of Medical Device and Regulatory services. We have connected with the best industry networks in the segment to provide the end to end solution at global scale. We are building industry best resources, potential clients and continuously working on the strategic collaborations to further strengthen the deliverables of our services. We have developed new commercial business model by incorporating the real-time response of the world market in the segment to add more value to our products without compromising on the quality and safety of the patients. We are here to create a robust operating platform capable of delivering consistent growth under any conditions. We are driving our business using five core values - . Integrity and ethics, innovation, teamwork and constant drive. We are proud of the work that the team has accomplished in the past and now we are confident to deliver what we promise and will drive it safely and sustainable. DRDL is determined to become a game changer in the area of Clinical Trial and allied Clinical Research services. Our focus is on providing the services on next-generation platform that will bring the change into the future.